上升眼睛:阿司匹林对糖尿病视网膜病变的影响
Emily L Sammons1, Georgina Buck2, Louise J Bowman1
1Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Ophthalmology
|January 18, 2024
概括
在一项大型试验中,阿司匹林在预防可转移性糖尿病视网膜病变 (DR) 或危及视力的眼部出血方面没有显著的益处. 然而,这项研究提供了关于阿司匹林在糖尿病患者眼科安全性的保证.
科学领域:
- 眼科医生 眼科 眼科
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 临床前研究表明,阿司匹林可以预防糖尿病视网膜病变 (DR).
- 随机试验证据对阿司匹林对DR结果的疗效是有限的.
- 这项研究解决了对阿司匹林在DR中的作用的强有力的临床数据的需求.
研究的目的:
- 评估每日服用阿司匹林预防糖尿病视网膜病变的疗效.
- 评估日常阿司匹林对视力威胁的眼部出血的安全性.
- 为阿司匹林在糖尿病患者的治疗中扮演的角色提供随机证据.
主要方法:
- 一项ASCEND试验的副研究,这是一项双面罩,随机,安慰剂控制的研究.
- 参与了15480名英国糖尿病成年人,随机分配每天服用100毫克阿司匹林或安慰剂.
- 主要结局:可参考的DR/黄斑病和视力威胁的眼部出血,通过治疗意图分析.
主要成果:
- 在阿司匹林和安慰剂组之间,可转移的DR事件没有显著差异 (率比1.03,P=0.64).
- 视力威胁的眼部出血在两组之间没有统计学上显著的差异 (比率比率为0.89).
- 数据链接包括7360名参与者,平均随访时间为6.5年.
结论:
- 阿司匹林对糖尿病视网膜病变没有临床意义上的好处.
- 这项研究提供了关于阿司匹林眼科安全性的保证.
- 这些发现澄清了阿司匹林在DR管理中的有限作用.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
01:25Antihypertensive Drugs: Direct Renin Inhibitors
631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432